News | July 26, 2024
Glenmark Life Sciences posts Q1 FY25 PAT at Rs. 111.48 Cr
Glenmark Life Sciences has reported total income of Rs. 594.109 crores during the period ended June 30, 2024
Glenmark Life Sciences has reported total income of Rs. 594.109 crores during the period ended June 30, 2024
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024
RPG Life Sciences has reported total income of Rs. 167.79 crores during the period ended June 30, 2024
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
The Unit has been issued GMP Certification from ANVISA-Brazil
The approved ANDA is therapeutically equivalent to the reference listed drug product
The My Green Lab Certification is the gold standard for laboratory sustainability practices worldwide
Subscribe To Our Newsletter & Stay Updated
